- NCIt
- C45485
Loading cancer entity…
Loading cancer entity…
Clinical trials
4 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06239480 | SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations(SELVA) | active not recruiting | Phase 3 | 51 | Palvella Therapeutics, Inc.INDUSTRY | 1 | Mar 27, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Mar 27, 2026source: clinicaltrials